iiinova — where your digital self keeps evolving

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 19h

🍄 #BalkanFungus in 🇷🇴 - landmark meeting for #MedicalMycology I shared an update on #cryptococcus, from screening and early recognition to diagnosis & management. Early diagnosis can make all the difference 💙 Congratulations @efisg-escmid.bsky.social and the amazing Cluj team! @escmid.bsky.social

011

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 02/10/2026

Chronic liver disease can be destabilised by #influenza and other respiratory infections. Honored that our #ESGVH Chair, Prof. @oana-sandulescu.bsky.social joins the #ESWI Board to connect liver health, vaccination and respiratory prevention. @escmid.bsky.social @eswinfluenza.bsky.social

011

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 02/10/2026

A new #EUCIC #IPC cohort in Ljubljana 💫 Fantastic evolution in a program we were piecing together several years ago. #AMS take-home: Tailor your ab choice. Your AMS plan. To your country. Your setting. Your patient. Evidence travels. Good stewardship adapts. @escmid.bsky.social @eucic.bsky.social

021

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 25/09/2026

Truly honored to join #ESWI and to be part of such an exceptional group of board members&experts. Looking forward to contributing my expertise and exchanging ideas to advance influenza science and public health. Grateful for the opportunity. Excited for the work ahead. @eswinfluenza.bsky.social

012

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 18/09/2026

Honoured and proud that our Chair, Prof. @oana-sandulescu.bsky.social delivered a fantastic keynote at #ESCV2026 in Porto! “Practical ART decision-making in HIV-HBV coinfection” - a timely reminder that HBV status matters in ART decisions. #HIV #HBV @escvirology.bsky.social @escmid.bsky.social

031

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 18/09/2026

Friday morning = keynote time at #ESCV2026 in Porto! My keynote: Practical ART decision-making in HIV-HBV coinfection 4 patient trajectories 4 ART decisions 4 things to know The message? HBV matters. Thank you @escvirology.bsky.social 👏👏 @esgvh.bsky.social @escmid.bsky.social

112

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 13/09/2026

⏰ TIME TO REGISTER! 🌍 Major international experts in viral hepatitis - all in one place. Join ESGVH for 3 days covering hepatitis A–E, emerging viruses & challenging cases. 📅 27–29 Nov 2026 | 💻 Online 👉 Register now lnkd.in/e53ChGBN @escmid.bsky.social

011

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 10/09/2026

Starting in 3 hours! Join us: HCV Elimination: A Multi-society Perspective on Progress, Gaps and Next Steps 📅 10 September 2026 ⏰ 3 pm CEST 💻 Zoom 🔗 Participation is free. Register here: lnkd.in/e577hvey @aasldnews.bsky.social @idsainfo.bsky.social @inhsu.bsky.social @escmid.bsky.social

011

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 01/09/2026

A thought to carry into autumn 🍂 At #ESC2026, I was invited to discuss the cardioprotective role of high-dose flu vaccination for the elderly. A great example of ID&cardio shared responsibility for the same patient. Flu prevention is also CV prevention 💉❤️ @escardio.bsky.social @medscape.com

096

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 29/07/2026

Breakthroughs in #ViralHepatitis begin with shared commitment. Read below an excellent paper published in #Germs_MDPI by our valued #ESGVH EC leaders: Prof @oana-sandulescu.bsky.social, Prof M Maticic, Assoc Prof I Hasanoglu. 👉 brnw.ch/21x4vKJ @escmid.bsky.social #WorldHepatitisDay

011

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

European Centre for Disease Prevention and Control @ecdc.europa.eu · 28/07/2026

Effective solutions to control viral hepatitis already exist, including vaccination, harm reduction, testing and treatment. This #WorldHepatitisDay, the challenge is ensuring these life-saving interventions are accessible to everyone who needs them. bit.ly/WorldHepDay2026 #IDsky #EpiSky

056

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

European Centre for Disease Prevention and Control @ecdc.europa.eu · 28/07/2026

But gaps remain: ➡️ Hepatitis B vaccination coverage uneven across the EU/EEA ➡️ access to harm reduction services for people who inject drugs remains inadequate in many countries. Annual epidemiological report on Hepatitis B: www.ecdc.europa.eu/en/publicati... #Hepatitis #HepatitisB #HepatitisC

ecdc.europa.eu

Hepatitis B - Annual Epidemiological Report for 2024

For 2024, 30 EU/EEA countries reported 37 605 cases of hepatitis B virus (HBV) infection, corresponding to a crude rate of 7.5 cases per 100 000 population.

165

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

European Centre for Disease Prevention and Control @ecdc.europa.eu · 28/07/2026

No one should die from a disease that is preventable, diagnosable and treatable. Yet around 5M people in Europe live with chronic hepatitis B or C, and almost 60,000 people die each year from liver disease linked to these infections. More information about the situation: bit.ly/WorldHepDay2026

bit.ly

World Hepatitis Day 2026: Despite progress towards eliminating hepatitis in Europe, gaps in prevention measures keep 2030 targets out of reach

While Europe has made steady progress in preventing hepatitis B and C the region is set to miss the 2030 target to eliminate viral hepatitis as a public health threat.

11811

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Philippa Matthews @pippa-matt.bsky.social · 28/07/2026

On #WorldHepatitisDay we celebrate many advances created through partnership between science & healthcare across continents… while continuing to advocate for urgent action, resources & data. @whowpro.bsky.social @crick.ac.uk @worldhepalliance.bsky.social @ahri-news.bsky.social #MedSky #LiverSky 🧪

Collage of photos showing teams in South Africa and the UK, and data presented by the World Hepatitis Alliance highlighting the case of need for viral hepatitis

Slogan for World Hepatitis Day ‘let’s break it down’

032

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

World Hepatitis Alliance @worldhepalliance.bsky.social · 09/07/2026

Missed our first #WorldHepatitisDay webinar? Watch it back and download our new community briefing to understand the latest global hepatitis data and how we can accelerate action. Watch back the webinar here: bit.ly/4vZCQg0 Download the briefing: bit.ly/4y45pdA

011

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 09/07/2026

#MaPaCi2026, Tg Mures Multidisciplinary care begins by seeing the person beyond the diagnosis. For people living with viral hepatitis or HIV, trust and reducing stigma are essential parts of care. Medicine is strongest when knowledge, compassion, and collaboration come together. #WEEPIFoundation

052

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 12/06/2026

#ID are major challenges in pregnancy, with potential consequences across generations. As co-organizer of the @escmid.bsky.social course Two Lives at Risk, @esgvh.bsky.social proudly spotlights #ViralHepatitis in pregnancy: maternal-fetal health&transmission prevention. @oana-sandulescu.bsky.social

010

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 21/05/2026

One week left to register for the @escmid.bsky.social course: "Navigating infectious diseases in pregnancy", proudly supported by @esgvh.bsky.social. Keynote lectures from distinguished experts: @oana-sandulescu.bsky.social, Gülşen Özkaya Şahin, Heli Harvala. Register at the link: lnkd.in/dadZHyBA

lnkd.in

This link will take you to a page that’s not on LinkedIn

011

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 25/03/2026

#ESGVH is proud to organize the #HIV Advanced Training Forum 2026 in Bucharest, led by Prof. @oana-sandulescu.bsky.social & Assoc. Prof. Juan Ambrosioni. A 2-day course empowering early-career clinicians with practical, evidence-based HIV care. @eacsociety.bsky.social @escmid.bsky.social

022

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 05/03/2026

Our collaborative webinar @esgvh.bsky.social and #UCHID is starting now! Our Chair, Prof @oana-sandulescu.bsky.social will talk about Rethinking priorities for viral hepatitis management. Today at 11.00 CET! Registration is free: us06web.zoom.us/webinar/regi... @escmid.bsky.social

us06web.zoom.us

010

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 07/02/2026

For 3 days, 🇷🇴 Romania was an international hub for #IPC training, part of the #EUCIC certificate Participants from 10 countries came together: 🇬🇧 🇩🇪 🇮🇹 🇪🇸 🇸🇮 🇧🇦 🇲🇹 🇹🇷 🇰🇷 🇷🇼 to explore how molecular&bioinformatics tools support surveillance and improve patient safety @escmid.bsky.social @eucic.bsky.social

031

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 06/02/2026

Delighted to partner with #UCHID for this impactful webinar on Treatment for all in HBV. #ESGVH is represented by our Chair, Prof @oana-sandulescu.bsky.social, and EC members Prof Nabil, Assoc Prof Hasanoglu. 📅 March 5, 11 PM CET 🔗 Register: us06web.zoom.us/webinar/regi... @escmid.bsky.social

011

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 18/12/2025

📢 Join us for a #HepDelta webinar by world class speakers: #ESGVH 🤝 #SOLDA Hepatitis Delta: Challenges in Diagnosis & Management 💻 Online, today ⏰ 11 a.m. CET 🔗 Register for free: lnkd.in/g5AXFGdv #WebSymposium #ViralHepatitis @esgvh.bsky.social @escmid.bsky.social @oana-sandulescu.bsky.social

022

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 23/11/2025

#ESGVH message for #HepTestWeek 25: Testing saves lives. Awareness drives change. Action moves us forward. 🩺 Early diagnosis = timely treatment 🤝 Normalize testing, reduce stigma 🌍 Elimination is possible if we act now @escmid.bsky.social @worldhepalliance.bsky.social @oana-sandulescu.bsky.social

033

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 19/10/2025

🌍 Proud of #ESGVH Chair Prof @oana-sandulescu.bsky.social for her inspiring role at #EACS2025 in Paris! 🎓🎤 Now Vice Chair of #YING, she’s advancing education & building bridges 🌉 between #ESCMID 🦠 and #EACS 🧬 for a healthier, more connected future 🌐💫 @escmid.bsky.social @eacsociety.bsky.social

031

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 18/10/2025

Also at #EACS2025 🇫🇷✨ Privileged to speak on advancing #HIV #PrEP equity 🌍 and improving access 💉💊 #EACS2025 was not only a platform for learning 📚 and collaboration 🙌 but also a chance to reconnect with friends 🤗 Grateful to be part of this passionate community 🤍 @eacsociety.bsky.social

072

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 18/10/2025

#EACS2025 🇫🇷✨ It was a pleasure co-organizing the Educational Course with the incredible #YING Faculty. Excited to step in as #EACS #YING Vice Chair and work with our new Chair Jose Bernardino following in the steps of @tristanjbarber.bsky.social 🙌 @eacsociety.bsky.social #HIV #GlobalHealth

032

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

European AIDS Clinical Society @eacsociety.bsky.social · 16/10/2025

#EACS2025- Oana Sandulescu is talking about advancing #PrEP equity across #Europe by integrating policy, community and clinical approaches, integrating PrEP delivery, reaching underserved populations, simplifying access and supporting community-led and peer-based models.

063

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Jesica Abadia @jessabbey.bsky.social · 16/10/2025

PrEP around Europe.. are we leaving anyone behind? @oana-sandulescu.bsky.social #EACS2025 there are a lot of hidden barriers to Access, are we doing our best to mitigate them?

Diapositiva que resume barreras ocultas para el acceso a PrEP

022

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 15/10/2025

✨ Great start to #EACS2025 🎤 Amazing @tristanjbarber.bsky.social opens the pre-conf Ed Course that features a stellar mix: clinical cases + research 🔍 🧬 Malignancies 🦠 Virology 💭 Stigma ⚖️ Weight 🔮 Future of ART 🎓 Research & Education Excited for what’s ahead for #YING! 🚀 @eacsociety.bsky.social

273

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 12/09/2025

A truly insightful exchange of knowledge with outstanding experts at the ESCMID #VaccinesConference @escmid.bsky.social Gulsen Ozkaya Sahin @casandrabulescu.bsky.social Susanne Gjeruldsen Dudman @oana-sandulescu.bsky.social Zeinab Nabil Mario Mondelli @taescmid.bsky.social @esgvh.bsky.social

011

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 12/09/2025

Inspiring session at the ESCMID #VaccinesConference! 🌍 This morning's hepatitis elimination session featured expertly delivered presentations from @esgvh.bsky.social members @oana-sandulescu.bsky.social, Susanne Dudman, Zeinab Nabil, and Mario Mondelli. An insightful morning 👏 @escmid.bsky.social

010

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 12/09/2025

✨ Day 3 at @escmid.bsky.social #VaccinesConference Now up 👉 Eliminating Hepatitis by 2030: How Vaccines are Key to Achieving WHO’s Vision? Fascinating fresh perspectives from international experts 🌍 Honored to join this outstanding panel and contribute to a thought-provoking conversation 🙌✨

111

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

ESCMID @escmid.bsky.social · 11/09/2025

Break time is networking time at the #VaccinesConference! Day 2 kicked off with a session on #vaccines against gastrointestinal infections and some great abstract presentations. Now attendees can enjoy a short break before the next set of sessions start focused on #OneHealth. #IDsky

121

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

ESCMID @escmid.bsky.social · 11/09/2025

Fantastic session on vaccine licensing covering aspects from fighting ongoing outbreaks, limited clinical data, and the current latest developments in the pipeline. Featuring Marco Cavaleri, Sarah Gilbert, Teresa Lambe and Annelies Wilder-Smith. @ema.europa.eu #VaccinesConference #Vaccines #IDSky

043

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 11/09/2025

Delighted to have chaired this session at the #VaccinesConference by @escmid.bsky.social Covering updates in CMV, RSV, and pertussis, the take home message is: Use the vaccines we have and foster research for future developments in vaccinology. 💉🔬 Now up, a thought provoking keynote lecture.

011

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 30/07/2025

A pleasure to be part of the scientific committee for this event. Make sure to join us in Bucharest on 5-6 Nov and submit your abstracts by 19 Sep to showcase your research. amededu.co/45sJDE0

amededu.co

9th Central and Eastern European Meeting on Viral Hepatitis and HIV 2025

In-Person event focusing on HIV, HIV, Viral Hepatitis and Liver Disease, RSV, COVID-19. 2025-11-05 to 2025-11-06 in Bucharest

021

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

World Hepatitis Alliance @worldhepalliance.bsky.social · 28/07/2025

Today is #WorldHepatitisDay! Let's break down all the obstacles hindering the elimination of viral hepatitis. Read our president's address! www.worldhepatitisalliance.org/news/world-h...

056

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Philippa Matthews @pippa-matt.bsky.social · 28/07/2025

Research is crucial to inform better interventions for #diagnosis, #prevention & #treatment of viral #hepatitis for different people in different settings. Global collaboration essential! #WorldHepatitisDay #NoHep #HBV @crick.ac.uk @ahri-news.bsky.social @cnwl.nhs.uk @ucllifesciences.bsky.social 🧪

1236

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 18/07/2025

📢 Call to young researchers: On behalf of the @esgvh.bsky.social Publication Subcommittee, Prof Zeinab Nabil is assessing challenges for early-career CM and ID physicians in research. If you are an early career MD, fill out the survey below: lnkd.in/dkQbmWqQ @escmid.bsky.social

lnkd.in

This link will take you to a page that’s not on LinkedIn

011

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Oana Sandulescu @oana-sandulescu.bsky.social · 11/07/2025

🚨 Call for Papers! Extra Baggage: Preparing the Traveler with Medical Comorbidities 🌍✈️ Collection in Tropical Diseases, Travel Medicine & Vaccines (IF 2.2) Submit you work on chronic illness, travel prep, vaccines, & more. 📩 Info: bit.ly/3EBo9Kw #TravelMedicine @springernature.com

021

ESGVH (ESCMID Study Group for Viral Hepatitis) @esgvh.bsky.social · 03/07/2025

🚨 Today! 💡 High-level webinar 📢 World Hepatitis Day 2025 – Viral hepatitis cannot wait! Join a milestone event co-organized by: 🔹 ESGVH 🔹 ECDC 🔹 WHO Europe 🔹 WHA 📅 Today, 3 July 2025 🕚 11:00–12:00 CET 🔗 Register now: lnkd.in/dUipyqcp @esgvh.bsky.social @oana-sandulescu.bsky.social

120

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

European AIDS Clinical Society @eacsociety.bsky.social · 30/06/2025

We are at the @europarl.europa.eu for the EP Roundtable hosted by MEP @krzysztofsmiszek.bsky.social Today's discussions bring together policymakers, clinicians, researchers & community voices to address persistent barriers in the #HIV response and shape a united way forward.

022

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

ESCMID @escmid.bsky.social · 20/06/2025

The Emerging Infections Subcommittee launches ESCMID-AUMC Epi Alert! Aiming for weekly publication, these reports aim to provide summaries on emerging infections for busy healthcare professionals w/ direct links for further investigation & transparency. ow.ly/5Rrj50WcejS #IDSky #clinmicro

134

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

EASL @easlnews.bsky.social · 24/06/2025

Help shape #EASLCongress 2026! We’re gathering input from the hepatology community to build a relevant, inclusive, and impactful programme. Share your insights in our short survey + enter to win free registration. 👉 www.surveymonkey.com/r/6F9BRBD

011

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

ESCMID @escmid.bsky.social · 22/06/2025

📰 If you are looking to publish with one of ESCMID's journals 💡Did you know: Our publisher, Elsevier, holds agreements w/ selected academic institutions that could make you eligible for waiving open access fees...meaning you could publish for free. Learn more: www.elsevier.com/ope... #IDSky

elsevier.com

Open access agreements | Elsevier

Elsevier has reached open access agreements with several institutions. See the full list.

011

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

ESCMID @escmid.bsky.social · 25/06/2025

⌛Last chance to apply for attendance grants for the postgraduate course on 'Better methods'. Apply by 30 June! 🗓️ Athens, Greece, 28-30 Oct 🍂 💡More info: ow.ly/7mnN50VWeUy #IDSky #clinmicro #MedSky

013

Reposted by ESGVH (ESCMID Study Group for Viral Hepatitis)

Ecraid @ecraid.bsky.social · 18/06/2025

#DKY that in our post-grad course you can choose between two tracks, join parallel workshops, discuss real-world cases, & network with your peers? 💡 👀Check out the programme, apply for an attendance grant, or register directly to secure your place! ➡️ bit.ly/44a1tdn #IDSky #ResearchSky #Education

121